for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Teva Pharmaceutical Industries Ltd (ADR)

TEVA.N

現在値

12.22USD

変化

-0.35(-2.78%)

出来高

5,468,495

本日のレンジ

11.72

 - 

12.91

52週レンジ

6.07

 - 

18.14

∙ 約20分前の相場を表示しています。

適時開示

Calif. AG's Office: opioid settlement talks with distributors ongoing

Feb 14 (Reuters) - :California AG's office says "far along in the process of talks" and still negotiating with distributors on opioid settlement.California AG's office says to suggest settlement talks with distributors regarding opioids are off would be inaccurate.

Teva Reports Qtrly Earnings Per Share $0.10

Feb 12 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS.QTRLY NON-GAAP EPS $0.62.QTRLY GAAP EARNINGS PER SHARE $0.10.2020 REVENUES ARE EXPECTED TO BE $16.6 - $17.0 BILLION.TEVA PHARMACEUTICAL - GENERIC PRODUCTS REVENUES IN OUR NORTH AMERICA SEGMENT IN Q4 OF 2019 INCREASED BY 3% TO $1,137 MILLION, COMPARED TO Q4 OF 2018.2020 NON-GAAP EPS IS EXPECTED TO BE $2.30 - $2.55.2020 FREE CASH FLOW IS EXPECTED TO BE $1.8 - $2.2 BILLION.AS OF DECEMBER 31, 2019, OUR DEBT WAS $26,908 MILLION, COMPARED TO $28,916 MILLION AS OF DECEMBER 31, 2018.TEVA PHARMACEUTICAL INDUSTRIES - COPAXONE REVENUES IN OUR NORTH AMERICA SEGMENT IN Q4 OF 2019 DECREASED BY 26% TO $264 MILLION, COMPARED TO Q4 OF 2018.QTRLY REVENUES $4,468 MILLION VERSUS $4,418 MILLION.TEVA PHARMACEUTICAL INDUSTRIES - COPAXONE REVENUES IN OUR EUROPE SEGMENT IN Q4 OF 2019 DECREASED BY 10% TO $106 MILLION, COMPARED TO Q4 OF 2018.IN 2020, CO EXPECT TO SEE CONTINUED GROWTH FOR AJOVY, AUSTEDO AND OUR BIOSIMILARS.

Teva Announces Positive Top-Line Results From Ajovy® (Fremanezumab) Clinical Trials In Japan

Feb 3 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM AJOVY® (FREMANEZUMAB) CLINICAL TRIALS IN JAPAN.AJOVY WAS WELL TOLERATED WITH A SIMILAR ADVERSE EVENTS PROFILE COMPARED TO PLACEBO.TEVA PHARMACEUTICAL - AJOVY'S PRELIMINARY RESULTS INDICATED PRIMARY ENDPOINTS ACHIEVED WITH BOTH CLINICAL, STATISTICAL SIGNIFICANCE VERSUS PLACEBO.

Teva Announces FDA Approval Of Ajovy Injection Autoinjector

Jan 28 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA ANNOUNCES FDA APPROVAL OF AJOVY® (FREMANEZUMAB-VFRM) INJECTION AUTOINJECTOR.TEVA PHARMACEUTICAL INDUSTRIES LTD - AJOVY AUTOINJECTOR IS EXPECTED TO BE AVAILABLE TO PATIENTS IN COMING MONTHS.

Ironwood And Allergan Announce Settlement With Teva Resolving Linzess (Linaclotide) Patent Litigation

Jan 22 (Reuters) - Ironwood Pharmaceuticals::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT WITH TEVA RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.IRONWOOD PHARMACEUTICALS - SETTLEMENT DOES NOT GRANT ANY LICENSE TO TEVA WITH REGARD TO ITS 72 MCG GENERIC VERSION OF LINZESS.IRONWOOD PHARMACEUTICALS - SETTLEMENT WITH TEVA REPRESENTS FINAL OUTSTANDING LINZESS PATENT LITIGATION.IRONWOOD PHARMACEUTICALS - EARLIEST LICENSED ENTRY OF ANY GENERIC LINACLOTIDE 145 MCG OR 290 MCG IN U.S. IS MARCH 2029.IRONWOOD PHARMACEUTICALS - ADDITIONAL DETAILS REGARDING SETTLEMENT WERE NOT DISCLOSED.IRONWOOD - HATCH-WAXMAN LITIGATION BETWEEN CO, ALLERGAN & TEVA REGARDING LINZESS PATENTS PENDING IN U.S. DISTRICT COURT FOR DISTRICT OF DELAWARE DISMISSED.IRONWOOD PHARMACEUTICALS - CO, ALLERGAN PURSUING ADDITIONAL PATENT APPLICATIONS COVERING FORMULATIONS RELATED TO LINZESS 72 MCG DOSAGE STRENGTH.

Ironwood, Allergan Announce Settlement Resolving Linzess (Linaclotide) Patent Litigation

Jan 6 (Reuters) - Ironwood Pharmaceuticals <IRWD.O>::IRONWOOD AND ALLERGAN ANNOUNCE SETTLEMENT RESOLVING LINZESS® (LINACLOTIDE) PATENT LITIGATION.CO, ALLERGAN REACH DEAL WITH SANDOZ RESOLVING LINZESS (LINACLOTIDE) PATENT LITIGATION.CO, ALLERGAN TO GRANT SANDOZ LICENSE TO MARKET 145 MCG & 290 MCG GENERIC VERSION OF LINZESS IN U.S. BEGINNING FEB 5, 2030.HATCH-WAXMAN LITIGATION BETWEEN COS & SANDOZ REGARDING LINZESS PATENTS PENDING IN US DISTRICT COURT FOR DISTRICT OF DELAWARE TO BE DISMISSED.IRONWOOD PHARMACEUTICALS- COMPANIES WILL SUBMIT SETTLEMENT AGREEMENT TO U.S. FEDERAL TRADE COMMISSION AND U.S. DEPARTMENT OF JUSTICE FOR REVIEW.PATENT INFRINGEMENT LITIGATION BROUGHT BY COS AGAINST TEVA PHARMACEUTICALS USA REMAIN PENDING.TRIAL THAT WAS SCHEDULED TO BEGIN ON JAN 7 HAS BEEN POSTPONED TO ENABLE PARTIES TO CONTINUE SETTLEMENT NEGOTIATIONS.

Teva, In Response To Report On Probe Of Opioid Makers, Distributors, Says Subpoena Referenced On Nov. 26 Was Previously Disclosed In Q3 Public Filings

Nov 26 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA, IN RESPONSE TO REPORT ON PROBE OF OPIOID MAKERS, DISTRIBUTORS, SAYS SUBPOENA REFERENCED ON NOV. 26 WAS PREVIOUSLY DISCLOSED IN Q3 PUBLIC FILINGS.TEVA SAYS AS NOTED IN CO’S PUBLIC SECURITIES FILINGS FOR Q3, TEVA "IS COOPERATING WITH THE SUBPOENA".

Federal Prosecutors Launch Criminal Probe Of Opioid Makers, Distributors - WSJ

Nov 26 (Reuters) - :FEDERAL PROSECUTORS LAUNCH CRIMINAL PROBE OF OPIOID MAKERS, DISTRIBUTORS - WSJ, CITING SOURCES.

Health Canada Says Apotex, Astrazeneca Canada, Teva Canada Reported Tamoxifen Shortages In The Past Weeks

Nov 20 (Reuters) - Health Canada :INFORMATION UPDATE - HEALTH CANADA UPDATE ON TAMOXIFEN SHORTAGE.HEALTH CANADA - FOR PAST SEVERAL WEEKS, APOTEX, ASTRAZENECA CANADA, TEVA CANADA HAVE REPORTED TAMOXIFEN SHORTAGES ON DRUG SHORTAGES CANADA WEBSITE.HEALTH CANADA - REASONS FOR TAMOXIFEN SHORTAGE REPORTED BY COS INCLUDED UNEXPECTED MANUFACTURING DISRUPTIONS & INCREASED DEMAND.HEALTH CANADA - WHILE TAMOXIFEN REMAINS AVAILABLE WITHIN HEALTHCARE SYSTEM, SUPPLY LEVELS HAVE BEEN LOWER THAN NORMAL.HEALTH CANADA - MITIGATION MEASURES FOR TAMOXIFEN SHORTAGE INCLUDED EXPLORING ACCESS TO INTERNATIONAL SUPPLY.HEALTH CANADA - ASTRAZENECA CANADA AND APOTEX HAVE BEEN ABLE TO EXPEDITE TAMOXIFEN SUPPLY.HEALTH CANADA - ASTRAZENECA CANADA, APOTEX NOW REPORTING EARLIER ANTICIPATED SHORTAGE END DATES OF DEC 6, 2019, AND DEC 31, 2019, RESPECTIVELY.HEALTH CANADA - TEVA CANADA CONTINUES TO REPORT AN ANTICIPATED TAMOXIFEN SHORTAGE END DATE OF JAN 31, 2020.

Teva Announces Upsize Of Senior Notes Offering & Pricing Of $2.1 Bln Of Senior Notes

Nov 19 (Reuters) - Teva Pharmaceutical Industries Ltd <TEVA.TA>::TEVA ANNOUNCES SUCCESSFUL UPSIZE OF SENIOR NOTES OFFERING AND PRICING OF $2.1 BILLION OF SENIOR NOTES.TEVA SAYS PRINCIPAL AMOUNT OF OFFERING WAS INCREASED FROM PREVIOUSLY ANNOUNCED OFFERING SIZE OF $1.5 BILLION.TEVA - NOTES CONSIST OF $1.0 BILLION OF 7.125% USD-DENOMINATED SENIOR NOTES MATURING IN 2025.TEVA - NOTES ALSO CONSIST OF EUR 1.0 BILLION OF 6.000% EUR-DENOMINATED SENIOR NOTES MATURING IN 2025.TEVA PHARMACEUTICAL INDUSTRIES LTD - SETTLEMENT OF NOTES IS EXPECTED TO OCCUR ON OR ABOUT NOV 25.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up